NEW YORK (GenomeWeb News) – PGXL Technologies today said that it has been awarded a $300,000 contract from the National Cancer Institute to advance research directed at circulating tumor cells for the early detection of cancer.

The Louisville, Ky.-based firm, a sister company to PGXL Laboratories, uses a technology called DEPArray, developed by Silicon Biosystems. The two firms said in April they were collaborating to make the technology available through PGXL.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.